Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="CANON, JL" or (type any "bookEditor issueEditor" and editor="CANON, JL")

Add to list
ROSALINE : a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast

E Agostinetto, G Nader-Marta, M Paesmans, L Ameye, I Veys, L Buisseret, P Neven, D Taylor, C Fontaine, FP Duhoux, et al.

(2022) FUTURE ONCOLOGY. 18(22). p.2381-2392
Add to list
High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)

NATACHA VERBEKE (UGent) , Yves Beguin, Hans Wildiers, JL Canon, Greet Bries, André Bosly and Simon Van Belle (UGent)

(2012) SUPPORTIVE CARE IN CANCER. 20(1). p.23-28
Add to list
- Journal Article
- A1
Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities

I Van Vlaenderen, JL Canon, Veronique Cocquyt (UGent) , G Jerusalem, JP Machiels, P Neven, M Nechelput, I Delabaye, M Gyldmark and Lieven Annemans (UGent)

(2009) ACTA CLINICA BELGICA. 64(2). p.100-112
Add to list
- Journal Article
- A1
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, M DiBartolomeo, MA Mazier, JL Canon, V Georgoulias, Marc Peeters (UGent) , et al.

(2009) ANNALS OF ONCOLOGY. 20(11). p.1842-1847
Add to list
- Journal Article
- A1
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

E VAN CUTSEM, S SIENA, Y HUMBLET, JL CANON, J MAUREL, E BAJETTA, B NEYNS, D KOTASEK, A SANTORO, W SCHEITHAUER, et al.

(2008) ANNALS OF ONCOLOGY. 19(1). p.92-98
Add to list
- Journal Article
- A1
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

E VAN CUTSEM, Marc Peeters (UGent) , S SIENA, Y HUMBLET, A HENDLISZ, B NEYNS, JL CANON, JL VAN LAETHEM, J MAUREL, G RICHARDSON, et al.

(2007) JOURNAL OF CLINICAL ONCOLOGY. 25(13). p.1658-1664
Add to list
- Journal Article
- A1
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer

JP MACHIELS, C SEMPOUX, P SCALLIET, JC COCHE, Y HUMBLET, E VAN CUTSEM, J KERGER, JL CANON, Marc Peeters (UGent) , S AYDIN, et al.

(2007) ANNALS OF ONCOLOGY. 18(4). p.738-744
Add to list
- Journal Article
- A1
OPTIMAL COMBINATION THERAPY WITH NAVOBAN(R) (TROPISETRON) IN PATIENTS WITH INCOMPLETE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.

Simon Van Belle (UGent) , Veronique Cocquyt (UGent) , H BLEIBERG, JL CANON, M BUYSE, F HULSTAERT, M DEWITTE, P DEKEYSER and K WESTELINCK

(1995) ANTI-CANCER DRUGS.
Add to list
- Journal Article
- A1
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.

M MARCHAND, P WEYNANTS, E RANKIN, F ARIENTI, F BELLI, G PARMIANI, N CASCINELLI, A BOURLOND, R VANWIJCK, Y HUMBLET, et al.

(1995) INTERNATIONAL JOURNAL OF CANCER. 63(6). p.883-885
Add to list
- Journal Article
- A1
OPTIMAL COMBINATION THERAPY WITH TROPISETRON IN 445 PATIENTS WITH INCOMPLETE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.

F HULSTAERT, S VANBELLE, H BLEIBERG, JL CANON, M DEWITTE, M BUYSE, P DEKEYSER and KJ WESTELINCK

(1994) JOURNAL OF CLINICAL ONCOLOGY. 12(11). p.2439-2446

Academic Bibliography

ROSALINE : a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast

High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008)

Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer

OPTIMAL COMBINATION THERAPY WITH NAVOBAN(R) (TROPISETRON) IN PATIENTS WITH INCOMPLETE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.

OPTIMAL COMBINATION THERAPY WITH TROPISETRON IN 445 PATIENTS WITH INCOMPLETE CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.

Contents

Support

Contact